Alteogen announces 80 billion won expansion of tax-free dividend resources and shareholder return initiatives, while strengthening governance through board restructuring and audit committee establishment ahead of planned KOSPI market transfer listing.
#YonhapInfomax #Alteogen #TaxFreeDividend #ShareholderReturns #KospiListing #CorporateGovernance #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=110151
Alteogen Expands Tax-Free Dividend Resources by 80 Billion Won, Advances Shareholder Returns
Alteogen announces 80 billion won expansion of tax-free dividend resources and shareholder return initiatives, while strengthening governance through board restructuring and audit committee establishment ahead of planned KOSPI market transfer listing.
JW Holdings acquires 100% stake in bio-focused VC Solidus Investment for 30.6 billion won, expanding portfolio with firm known for investments in Alteogen, Orum Therapeutics, and Ollix, while managing multiple bio-healthcare funds targeting promising biotech companies in South Korea's growing life sciences sector.
#YonhapInfomax #JWHoldings #SolidusInvestment #BiotechVC #Alteogen #HealthcareFund #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=109819Alteogen Inc. reported a 275% year-on-year surge in 2023 operating profit to 1.148 trillion won, with revenue more than doubling, reflecting robust growth in South Korea's biopharmaceutical sector.
#YonhapInfomax #Alteogen #OperatingProfit #Revenue #Biopharmaceutical #YearOnYearGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=103316
Alteogen Posts 275% Surge in 2023 Operating Profit to 114.8 Billion Won
Alteogen Inc. reported a 275% year-on-year surge in 2023 operating profit to 1.148 trillion won, with revenue more than doubling, reflecting robust growth in South Korea's biopharmaceutical sector.
Alteogen Posts 275% Surge in 2023 Operating Profit to KRW 114.8 Billion
Alteogen, a South Korean biopharmaceutical company, reported a 275% year-on-year jump in 2023 operating profit, reaching KRW 114.8 billion.
Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
#YonhapInfomax #Alteogen #TechnologyTransfer #ShinhanInvestment #OptionAgreement #TargetPrice730000Won #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=97468
Global Pharma Firms Pay to Get in Line for Alteogen’s Technology—Target Price Set at 730,000 Won
Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
Alteogen Inc. has named Jeon Tae-yeon as its new CEO, with founder Park Soon-jae stepping down from the chief executive role but remaining as board chairman, signaling a leadership transition at the South Korean biopharma firm.
#YonhapInfomax #Alteogen #JeonTaeYeon #ChiefExecutiveOfficer #ALTB4 #LeadershipTransition #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=97313
Alteogen Appoints Jeon Tae-yeon as New CEO—Chairman Park Soon-jae Steps Down
Alteogen Inc. has named Jeon Tae-yeon as its new CEO, with founder Park Soon-jae stepping down from the chief executive role but remaining as board chairman, signaling a leadership transition at the South Korean biopharma firm.
KOSDAQ Bellwether Alteogen Plunges 14% After 'Keytruda SC' Sales Ban in Germany
Alteogen shares plunged over 14% after a German court banned sales of partner Merck’s Keytruda SC, clouding royalty and milestone revenue prospects in Europe.
South Korea's KOSPI and KOSDAQ indices fell in early trading as investors awaited U.S. inflation data, with major stocks like SK hynix and Alteogen posting notable declines amid a lack of clear market drivers.
#YonhapInfomax #KOSPI #KOSDAQ #SKHynix #Alteogen #PCEPriceIndex #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=94098
KOSPI and KOSDAQ Decline in Absence of Market Catalysts
South Korea's KOSPI and KOSDAQ indices fell in early trading as investors awaited U.S. inflation data, with major stocks like SK hynix and Alteogen posting notable declines amid a lack of clear market drivers.
Alteogen Co. posted a 900% jump in Q3 revenue, driven by the commercialization of its ALT-B4 platform and milestone payments from FDA-approved Keytruda SC, marking a major turnaround in profitability and global expansion momentum.
#YonhapInfomax #Alteogen #ALTB4 #Q3Revenue #Keytruda #FDAApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=90913
Alteogen Posts 900% Surge in Q3 Revenue as ALT-B4 Commercialization Accelerates
Alteogen Co. posted a 900% jump in Q3 revenue, driven by the commercialization of its ALT-B4 platform and milestone payments from FDA-approved Keytruda SC, marking a major turnaround in profitability and global expansion momentum.
Yonhap Infomax News